Patents by Inventor Ho Young Song

Ho Young Song has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240181943
    Abstract: An embodiment luggage gap cover device for a rear seat of a vehicle is provided. The rear seat includes an interlocking frame connecting a seatback of the rear seat to a seat cushion for a dive operation, and the luggage gap cover device includes a foldable cover mat on a rear surface of the seatback configured to cover a gap between the seatback and a floor plate of a luggage compartment and a support protrusion on the interlocking frame, the support protrusion being configured to push and support the cover mat in a direction of covering the gap between the seatback and the floor plate.
    Type: Application
    Filed: May 2, 2023
    Publication date: June 6, 2024
    Inventors: Mu Young Kim, Jun Young Yun, Han Kyeol Cho, Ho Suk Jung, Sang Do Park, Chan Ho Jung, Jun Hwan Lee, Dong Jin Kim, Hee Won Kwon, Jung Eun Kwon, Soo Yong Kim, Ye Eun Song, Jeong Su Yoon
  • Patent number: 11994948
    Abstract: A semiconductor memory device includes a memory cell array, an error correction circuit, an error log register and a control logic circuit. The memory cell array includes a plurality of memory bank arrays and each of the memory bank arrays includes a plurality of pages. The control logic circuit is configured to control the error correction circuit to perform an ECC decoding sequentially on some of the pages designated at least one access address for detecting at least one bit error, in response to a first command received from a memory controller. The control logic circuit performs an error logging operation to write page error information into the error log register and the page error information includes a number of error occurrence on each of the some pages determined from the detecting.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: May 28, 2024
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hoi-Ju Chung, Sang-Uhn Cha, Ho-Young Song, Hyun-Joong Kim
  • Publication number: 20240170266
    Abstract: The present invention provides a component for a semiconductor device fabrication apparatus, a semiconductor device fabrication apparatus including the same, and a method of fabricating a semiconductor device, wherein the component includes single-crystal silicon, wherein, on at least one surface thereof, a water contact angle is 45° to 74° and a diiodomethane contact angle is 41° to 57°.
    Type: Application
    Filed: November 17, 2023
    Publication date: May 23, 2024
    Inventors: Hyun Soo LEE, Hae Mi KANG, Do Hyun CHOI, Il Gu YONG, Jong Kyu LEE, Ho Geun HAN, Ju Young SONG
  • Patent number: 11975076
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: May 7, 2024
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20240132940
    Abstract: The present invention relates to a fluorescent reporter capable of labeling nucleic acids including DNA and exhibiting luminescent properties at an excited energy level, and various uses thereof.
    Type: Application
    Filed: September 5, 2023
    Publication date: April 25, 2024
    Applicant: SFC CO., LTD.
    Inventors: Do Min LEE, Ho Young SI, Jae Hyung JO, Goutam MASANTA, Ju Man SONG, Min Su EUM, Jong Tae JE
  • Publication number: 20240131178
    Abstract: The present disclosure relates to a novel antibody-drug conjugate (ADC) targeting claudin 18 isoform 2 (CLDN18.2), an active metabolite of the ADC, a method of producing the ADC, use of the ADC for the treatment and/or prevention of diseases, and use of the ADC for producing a drug for the treatment and/or prevention of diseases, more specifically hyperproliferative and/or angiogenic diseases, for example, cancer, and more particularly, to an antibody-drug conjugate including a novel antibody or antigen-binding fragment thereof that binds to CLDN18.2, and a pharmaceutical composition including the same.
    Type: Application
    Filed: March 30, 2022
    Publication date: April 25, 2024
    Applicants: LEGOCHEM BIOSCIENCES, INC., NONA BIOSCIENCES (SUZHOU) CO., LTD.
    Inventors: Chang Sik PARK, Ho Young SONG, Tae Ik JANG, Chul-Woong CHUNG, Ming-jin JHENG
  • Publication number: 20230405139
    Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: June 13, 2023
    Publication date: December 21, 2023
    Inventors: Yun-Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
  • Patent number: 11827703
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: November 28, 2023
    Assignees: LegoChem Biosciences, Inc., NovImmune, SA
    Inventors: Ho Young Song, Yun Hee Park, Sung Min Kim, Hyoung Rae Kim, Ji Hye Oh, Hyun Min Ryu, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim, Maureen Deehan, Nicolas Fischer
  • Publication number: 20230310640
    Abstract: The present invention relates to a pyrrolobenzodiazepine derivative compound, a conjugate of the same with a ligand, and the use of the same. The pyrrolobenzodiazepine derivative compound is more stable in plasma, is stable even in circulation, and exhibits excellent efficacy. In particular, the conjugate of the pyrrolobenzodiazepine derivative compound with a ligand has a great advantage in that it is possible to target and specifically treat proliferative disease such as cancer, maximize drug efficacy, and minimize the expression of side effects since the conjugate more stably reaches the target cell and effectively exerts drug efficacy while toxicity is greatly reduced as a linker technology that allows drugs to be easily released within cancer cells and maximize drug efficacy is incorporated.
    Type: Application
    Filed: December 30, 2020
    Publication date: October 5, 2023
    Inventors: Ho Young SONG, Yun-Hee PARK, Kun Jung LEE, Ji Hye OH, Sung Min KIM, Kyung Eun PARK, Yong Gyu PARK, Hyun Min RYU, Na Ra HAN, Chul Woong CHUNG, Jei Wook CHAE, Yong Zu KIM
  • Publication number: 20230270868
    Abstract: The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.
    Type: Application
    Filed: February 24, 2023
    Publication date: August 31, 2023
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun-Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun Joung Lee, Ju Young Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Publication number: 20230272070
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: September 16, 2022
    Publication date: August 31, 2023
    Inventors: Ho Young Song, Yun Hee Park, Sung Min Kim, Hyoung Rae Kim, Ji Hye Oh, Hyun Min Ryu, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim, Maureen Deehan, Nicolas Fischer
  • Patent number: 11707533
    Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: July 25, 2023
    Assignees: LegoChem Biosciences, Inc., ABL Bio, Inc.
    Inventors: Yun-Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-Na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
  • Publication number: 20230185664
    Abstract: A semiconductor memory device includes a memory cell array, an error correction circuit, an error log register and a control logic circuit. The memory cell array includes a plurality of memory bank arrays and each of the memory bank arrays includes a plurality of pages. The control logic circuit is configured to control the error correction circuit to perform an ECC decoding sequentially on some of the pages designated at least one access address for detecting at least one bit error, in response to a first command received from a memory controller. The control logic circuit performs an error logging operation to write page error information into the error log register and the page error information includes a number of error occurrence on each of the some pages determined from the detecting.
    Type: Application
    Filed: February 3, 2023
    Publication date: June 15, 2023
    Inventors: Hoi-Ju CHUNG, SANG-UHN CHA, HO-YOUNG SONG, HYUN-JOONG KIM
  • Patent number: 11654197
    Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: May 23, 2023
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun Joung Lee, Ju Young Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Patent number: 11593199
    Abstract: A semiconductor memory device includes a memory cell array, an error correction circuit, an error log register and a control logic circuit. The memory cell array includes a plurality of memory bank arrays and each of the memory bank arrays includes a plurality of pages. The control logic circuit is configured to control the error correction circuit to perform an ECC decoding sequentially on some of the pages designated at least one access address for detecting at least one bit error, in response to a first command received from a memory controller. The control logic circuit performs an error logging operation to write page error information into the error log register and the page error information includes a number of error occurrence on each of the some pages determined from the detecting.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: February 28, 2023
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hoi-Ju Chung, Sang-Uhn Cha, Ho-Young Song, Hyun-Joong Kim
  • Publication number: 20220339291
    Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting DLK1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically, uses for such ADCs in producing drugs for treatment and/or prevention of proliferative and/or angiogenetic diseases, for example, cancer. More particularly, the present invention relates to an antibody-drug conjugate comprising an antibody binding with DLK1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: March 5, 2020
    Publication date: October 27, 2022
    Inventors: Chang Sik Park, Min Ji Choi, Tae Ik Jang, Yun-Hee Park, Ho Young Song, Ju Yuel Baek, Sung Min Kim, Hyeun Joung Lee, Ju Young Lee, Hyoung Rae Kim, Kun Jung Lee, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Sang Pil Lee, Ji-Young Shin, Sunha Yoon, Yunseon Choi, Jae Eun Park, Jisu Lee, Bum-Chan Park, Young Woo Park
  • Patent number: 11413353
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 16, 2022
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20220226496
    Abstract: The present invention relates to a ligand-drug conjugate including a ligand; a linker that is connected to the ligand by a covalent bond and has a tris structure represented by a specific structural formula; and an active agent connected to the linker by a covalent bond. In the ligand-drug conjugate, the active agent is bound by the tris structure of the linker, and thus a greater number of active agents can be connected through one linker. Accordingly, a greater number of active agents per antibody binding can be delivered to the target cell, and the drug and/or toxin can stably reach the target cell and effectively exert the drug efficacy.
    Type: Application
    Filed: April 29, 2020
    Publication date: July 21, 2022
    Inventors: Ho Young SONG, Yun-Hee PARK, Sang Eun CHAE, Ju Yuel BAEK, Kyung Eun PARK, Ju Young LEE, Su In LEE, Jeiwook CHAE, Chang Sun LEE, Yong Zu KIM
  • Publication number: 20220218830
    Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.
    Type: Application
    Filed: March 29, 2018
    Publication date: July 14, 2022
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun J. Lee, Ju Y. Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Publication number: 20220218840
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Application
    Filed: November 12, 2021
    Publication date: July 14, 2022
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee